EUCTR2005-001579-37-SE进行中（未招募）不适用
An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery - Study 311
Wyeth Research Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development0 个研究点目标入组 50 人开始时间: 2005年12月9日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Male subjects with hemophilia A- FVIII:C = 2%
- •- Age = 12 years
- •- A negative FVIII inhibitor at both the local laboratory and central laboratory at screening
- •- A negative past medical history of a FVIII inhibitor
- •- Previously treated with = 150 exposure days to any Factor VIII product
- •- The subject will be undergoing elective major surgery that is anticipated to require FVIII infusions and daily FVIII activity monitoring over a period of at least 6 days following surgery
- •- ALT (SGOT) and AST (SGPT) =5.0 x ULN, and bilirubin =2mg/dL (33 µmol/L)
- •- Serum albumin = LLN- Serum creatinine =1.25 x ULN- Platelet count = 100,000 /µL
- •- Absolute CD4 count >200 µL
- •- PT =1.25 x ULN or INR = 1.5
- •- Patients receiving therapy for HIV or Hepatitis infection, must be on a stable antiviral regimen at the time of study entry
- •- The patient should be able to comply with the mandatory 72-hour washout period as specified in the protocol
- •- The patient should be able to comply with the required inpatient length of
- •stay including at least 2 days for BI subjects and at least 6 days for all CI
- •The Global Medical Monitor should be consulted about prospective subjects with complex clinical or laboratory histories relevant to inclusion criteria.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- A history of FVIII inhibitor (clinical or laboratory based assessment, as defined in the protocol definitions), such as recurrent low titer values. Any measured Bethesda inhibitor titer greater than or equal to 0.6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda inhibitor titer greater than the upper limit of normal for the laboratory performing the assay
- •- Presence of a bleeding disorder in addition to hemophilia A
- •- Treatment with any investigational drug or device within the past 30 days, except for subjects entering from other studies of ReFacto AF
- •- Prior participation in this study (except for screen failures)
- •- Regular (e.g. daily, QOD) use of antifibrinolytic agents or medications known to influence platelet function such as aspirin or certain NSAIDs
- •- Concomitant therapy with immunosuppressive drugs (e.g., IVIG, routine systemic corticosteroids)
- •- Known hypersensitivity to hamster protein
- •- Unwilling or unable to follow the terms of the protocol
- •The Global Medical Monitor should be consulted about prospective subjects with complex clinical or laboratory histories relevant to exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major SurgeryMale subjects with hemophilia A (FVIII:C =2% confirmed at screening), previously treated with = 150 exposure days to any Factor VIII product, undergoing elective major surgery that is anticipated to require FVIII infusions over a period of at least 6 days following surgeryMedDRA version: 8.1Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIIEUCTR2005-001579-37-FRWyeth Research Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development50
进行中（未招募）
不适用
An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major SurgeryMale subjects with hemophilia A (FVIII:C =2% confirmed at screening), previously treated with = 150 exposure days to any Factor VIII product, undergoing elective major surgery that is anticipated to require FVIII infusions over a period of at least 6 days following surgeryEUCTR2005-001579-37-ATWyeth Research Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development50
进行中（未招募）
1 期
An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary EventMedDRA version: 7.0 Level: LLT Classification code 10020603hypercholesterolemiaEUCTR2004-002345-12-GB490
进行中（未招募）
不适用
An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary EventhypercholesterolemiaEUCTR2004-002345-12-ATMerck Sharp & Dohme Gesellschaft m.b.H.490
进行中（未招募）
1 期
An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary EventHypercolesterolemiaMedDRA version: 6.1 Level: HLT Classification code 10014476EUCTR2004-002345-12-ITMERCK SHARP DOHME450